Clinical Results and Testimonials for Dry Eye Treatment

Measurable Clinical Outcomes With a Structured Treatment Approach

Tixel-i demonstrates consistent performance in the management of evaporative dry eye when used within defined treatment protocols.

Observed dry eye clinical results show improvement in tear film stability, reduction in patient-reported symptoms, and support for meibomian gland function across treatment cycles. ¹&sup4;

These dry eye treatment outcomes support its role as a structured, in-office procedure designed for repeatable clinical delivery.

Proven Dry Eye Treatment Outcomes

Clinicians using Tixel-i report consistent and repeatable dry eye treatment outcomes in patients with evaporative dry eye and meibomian gland dysfunction.

Commonly observed dry eye clinical results include:
  • Improving tear film stability
    ¹1. Shah S, Dutta D, Barua A, Hanneken L, Naroo SA. The effect of non-ablative thermomechanical skin treatment (Tixel®️) on dry eye disease: A prospective two centre open-label trial. Cont Lens Anterior Eye. 2023;46(2):101811.

    ˒

    ³3. Safir M, Hecht I, Ahimor A, Zmujack-Yehiam S, Stein R, Bakshi E, Einan-Lifshitz A, Hartstein ME. The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease – a pilot prospective clinical trial. Cont Lens Anterior Eye. 2022;45(6):101741. doi:10.1016/j.clae.2022.101741.

    ˒

    ⁴4. Sadri E, Verachtert A, Parkhurst GD, Echegoyen J, Klein I, Agmon Y, Berdy GJ. Effectiveness and safety of a thermomechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction. J Cataract Refract Surg. 2025;51(4):274-281. doi:10.1097/j.jcrs.0000000000001602.
  • Reduction in patient-reported symptoms
    ¹1. Shah S, Dutta D, Barua A, Hanneken L, Naroo SA. The effect of non-ablative thermomechanical skin treatment (Tixel®️) on dry eye disease: A prospective two centre open-label trial. Cont Lens Anterior Eye. 2023;46(2):101811.

    ˒

    ³3. Safir M, Hecht I, Ahimor A, Zmujack-Yehiam S, Stein R, Bakshi E, Einan-Lifshitz A, Hartstein ME. The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease – a pilot prospective clinical trial. Cont Lens Anterior Eye. 2022;45(6):101741. doi:10.1016/j.clae.2022.101741.

    ˒

    ⁴4. Sadri E, Verachtert A, Parkhurst GD, Echegoyen J, Klein I, Agmon Y, Berdy GJ. Effectiveness and safety of a thermomechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction. J Cataract Refract Surg. 2025;51(4):274-281. doi:10.1097/j.jcrs.0000000000001602.
  • Support for meibomian gland function
    ³3. Safir M, Hecht I, Ahimor A, Zmujack-Yehiam S, Stein R, Bakshi E, Einan-Lifshitz A, Hartstein ME. The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease – a pilot prospective clinical trial. Cont Lens Anterior Eye. 2022;45(6):101741. doi:10.1016/j.clae.2022.101741.

    ˒

    ⁴4. Sadri E, Verachtert A, Parkhurst GD, Echegoyen J, Klein I, Agmon Y, Berdy GJ. Effectiveness and safety of a thermomechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction. J Cataract Refract Surg. 2025;51(4):274-281. doi:10.1097/j.jcrs.0000000000001602.
  • Sustained improvement following treatment protocols
    ²2. Sadri E, Verachtert A, Parkhurst GD, Echegoyen J, Klein I, Agmon Gerstein Y, Berdy GJ. Durability of treatment with a thermomechanical device in meibomian gland dysfunction: an observational extension study. J Ocul Pharmacol Ther. 2025. doi:10.1089/jop.2025.0033.

Practitioner Testimonials

Tixel’s ease of use and reproducible results make it ideal for both my trained staff and me. It’s a technology we trust daily to deliver visible improvements safely and without the worry of complications,
Dr. Amy B. Lewis, M.D.
You're going to find that there's so much of a demand, that you're better off having one in each location.
Dr. April Jasper, O.D.
In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction. After 2 Tixel i treatments, I no longer need punctal plugs or drops.
Dr. Debra Koloms, M.D.
I was part of the clinical study, so I was excited to purchase the first Tixel i because my patients reported significant relief of their symptoms.
Dr. Gregg J. Berdy, M.D.
I consider Tixel an essential device for any dry eye clinic, as it provides substantial therapeutic benefits while being easy to use.
Dr. Ludger Hanneken, M.D., PhD.
Our patients are happier than our cataract patients -- that's a very high bar and Tixel blew right past that!
Dr. Neil Notaroberto M.D.
Tixel requires no gel, no eye patches, and no assistant; the entire procedure is completed in about two minutes. Since then, I have applied Tixel to many patients with dry eye and MGD, including those with chalazia, and have observed consistently favorable outcomes.
Dr. Reiko Arita M.D, PhD.

Consistent Tixel Results in Practice

Tixel results are based on repeatable treatment protocols that allow clinicians to monitor progress over time.

Reported Tixel results show:
  • Progressive improvement throughout treatment cycles
  • Continued symptom improvement following completion
  • Consistent response when protocols are followed

These dry eye treatment outcomes support the use of structured treatment pathways within clinical practice.

Real Outcomes You Can Evaluate

You can assess how these outcomes translate into your clinical environment by reviewing data, protocols, and practitioner experience.

Tixel-i provides a controlled, in-office approach designed to deliver consistent performance across treatment cycles.